Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coeptis Therapeutics Holdings (COEP) Enterprise Value (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Enterprise Value data on record, last reported at -$4.8 million in Q3 2025.

  • For Q3 2025, Enterprise Value fell 387.77% year-over-year to -$4.8 million; the TTM value through Sep 2025 reached -$4.8 million, down 387.77%, while the annual FY2024 figure was -$47783.0, 96.75% up from the prior year.
  • Enterprise Value reached -$4.8 million in Q3 2025 per COEP's latest filing, down from -$2.0 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$47783.0 in Q4 2024 and bottomed at -$7.4 million in Q3 2022.
  • Average Enterprise Value over 5 years is -$2.2 million, with a median of -$2.0 million recorded in 2025.
  • Peak YoY movement for Enterprise Value: tumbled 1160.77% in 2022, then soared 96.75% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$2.2 million in 2021, then tumbled by 73.95% to -$3.8 million in 2022, then skyrocketed by 61.25% to -$1.5 million in 2023, then skyrocketed by 96.75% to -$47783.0 in 2024, then crashed by 9901.44% to -$4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$4.8 million in Q3 2025, -$2.0 million in Q2 2025, and -$3.3 million in Q1 2025.